$Invesco QQQ(QQQ)$ Hard to understand being unimpressed with a company whose Q3 revenue exceeded Q1 and Q2 combined. Some people just seem miserable for the sake of it.
$ImmunityBio, Inc.(IBRX)$ $Invesco QQQ(QQQ)$ $SPDR S&P 500 ETF Trust(SPY)$ IBRX Anktiva was approved for a bladder cancer indication last week that triples their patient potential. Almost immediately a big pharma writer at Stat News came out with negative coverage, even though the data was better and adverse events were lower than Merck's Keytruda. Analysts have raised or reiterated price targets. Then today more unknown writers showed up with negative takes. After an early 5% gain, shorts attacked the bids and it closed down 1.20. Short interest was 34% this morning, trapped unless they used illegal tactics to sow doubt. This kind of attack slow
$SPDR S&P 500 ETF Trust(SPY)$ $Invesco QQQ(QQQ)$ I'm closing out my short positions. The market looks set to rally into the close, and I'd wager we see a multi-day uptrend. October and November heading into midterms do tend to run positive.